Can a bedside heart ultrasound save lives in cirrhosis patients with sepsis?

NCT ID NCT07286643

Recruiting now Knowledge-focused Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two ways to manage fluids in cirrhosis patients with severe sepsis or septic shock. One method uses a bedside heart ultrasound (POCUS) to guide fluid amounts, while the other follows standard sepsis guidelines. The goal is to see if ultrasound-guided care reduces the amount of fluid needed and prevents complications like fluid buildup in the lungs. The trial will enroll 140 critically ill adults in the ICU.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Point-of-care echocardiogram (POCUS) guided fluid resuscitation
What this could lead to: If successful, this could establish a better way to manage fluids in cirrhosis patients with sepsis, potentially reducing lung complications and improving survival.
What could go wrong: This is a small, early feasibility trial (140 participants) at a single center. The approach may not show clear benefits over standard care, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver cirrhotic cardiomyopathy toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIRRHOSIS, LIVER CIRRHOTIC CARDIOMYOPATHY SEPTIC SHOCK

Contacts and locations

Locations

PGIMER Chandigarh
RECRUITING

Chandigarh, 160012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.